A 2-Dose AERAS-402 Regimen Boosts CD8
tuberculosis
AERAS-402
Phase 1 trial
T-cell responses
TB vaccine
transcriptional profiling
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
02
2021
accepted:
18
05
2021
entrez:
28
6
2021
pubmed:
29
6
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Despite the widespread use of BCG, tuberculosis (TB) remains a global threat. Existing vaccine candidates in clinical trials are designed to replace or boost BCG which does not provide satisfying long-term protection. AERAS-402 is a replication-deficient Ad35 vaccine encoding a fusion protein of the
Identifiants
pubmed: 34177914
doi: 10.3389/fimmu.2021.673532
pmc: PMC8231292
doi:
Substances chimiques
AERAS-402
0
BCG Vaccine
0
Tuberculosis Vaccines
0
Vaccines, DNA
0
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
673532Informations de copyright
Copyright © 2021 Sivakumaran, Blatner, Bakken, Hokey, Ritz, Jenum and Grewal.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
AIDS. 2004 May 21;18(8):1213-6
pubmed: 15166541
Vaccine. 2015 Aug 7;33(33):4130-40
pubmed: 26095509
Expert Rev Vaccines. 2011 Mar;10(3):255-7
pubmed: 21434793
BMC Med. 2016 May 16;14:76
pubmed: 27183822
Crit Rev Immunol. 2006;26(4):317-52
pubmed: 17073557
Science. 1998 Oct 2;282(5386):121-5
pubmed: 9756476
Science. 1997 May 30;276(5317):1420-2
pubmed: 9162010
Infect Immun. 2002 Mar;70(3):1623-6
pubmed: 11854254
Genomics. 2004 Jun;83(6):989-99
pubmed: 15177553
J Immunol Methods. 2015 Feb;417:22-33
pubmed: 25523923
Microbiol Rev. 1992 Dec;56(4):648-61
pubmed: 1480113
PLoS Pathog. 2009 Apr;5(4):e1000392
pubmed: 19381260
Vaccine. 2012 Mar 9;30(12):2098-108
pubmed: 22296955
Lancet. 2013 Mar 23;381(9871):1021-8
pubmed: 23391465
Semin Immunopathol. 2015 May;37(3):239-49
pubmed: 25917388
Vaccine. 2017 Mar 14;35(12):1652-1661
pubmed: 28216183
Sci Rep. 2016 Nov 02;6:36355
pubmed: 27805026
AIDS. 2009 Aug 24;23(13):1717-25
pubmed: 19461502
J Clin Microbiol. 2003 Nov;41(11):5046-52
pubmed: 14605137
PLoS Pathog. 2007 Sep 21;3(9):1240-9
pubmed: 17892322
J Immunol. 2005 May 15;174(10):6332-9
pubmed: 15879133
Lancet Infect Dis. 2014 Oct;14(10):939-46
pubmed: 25151225
Nucleic Acids Res. 2019 Jul 2;47(W1):W199-W205
pubmed: 31114916
Infect Immun. 2001 Apr;69(4):2714-7
pubmed: 11254639
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13853-8
pubmed: 11095745
J Immunol. 2007 Sep 15;179(6):3973-81
pubmed: 17785835
Vaccine. 2013 Feb 4;31(7):1026-33
pubmed: 23266342
Nature. 2010 Aug 19;466(7309):973-7
pubmed: 20725040
J Gen Virol. 2006 Aug;87(Pt 8):2135-2143
pubmed: 16847108
N Engl J Med. 2018 Jul 12;379(2):138-149
pubmed: 29996082
PLoS One. 2011 Jan 13;6(1):e16161
pubmed: 21249199
Sci Rep. 2017 Jul 19;7(1):5839
pubmed: 28724962
Infect Immun. 2000 Jan;68(1):214-20
pubmed: 10603390
J Immunol. 2013 Jan 1;190(1):270-7
pubmed: 23233724
J Immunol. 2007 Sep 15;179(6):3463-71
pubmed: 17785780
Am J Respir Crit Care Med. 2010 Jun 15;181(12):1407-17
pubmed: 20167847
Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12434-9
pubmed: 17640915
Pediatrics. 1995 Jul;96(1 Pt 1):29-35
pubmed: 7596718
J Immunol. 2000 Dec 1;165(11):6463-71
pubmed: 11086086
Am J Respir Crit Care Med. 2003 Dec 1;168(11):1346-52
pubmed: 12969871
Expert Rev Vaccines. 2012 Oct;11(10):1221-33
pubmed: 23176655
PLoS One. 2013 Sep 16;8(9):e73230
pubmed: 24066041
Immunology. 2018 Mar;153(3):325-336
pubmed: 28881482
Nat Med. 2004 Nov;10(11):1240-4
pubmed: 15502839
Infect Immun. 2002 Oct;70(10):5446-53
pubmed: 12228269